Impact of Systemic Treatments for Advanced Melanoma on Mesenteric Panniculitis Risk

Overview

This retrospective study evaluated the incidence of mesenteric panniculitis (MP) in advanced melanoma patients treated with immune checkpoint inhibitors (ICI) versus BRAF/MEK inhibitors (BRAFi/MEKi). Among 490 patients analyzed, BRAFi/MEKi treatment was associated with a significantly higher occurrence of MP compared to ICI therapy. These findings suggest a potential link between BRAFi/MEKi therapy and MP development.

Background

Melanoma, although comprising only 1% of skin cancers, accounts for the majority of skin cancer-related deaths. Advances in systemic therapies, including BRAFi/MEKi and ICI, have improved survival in advanced melanoma. However, these treatments carry distinct toxicity profiles, with BRAFi/MEKi linked to rare inflammatory side effects such as panniculitis. Mesenteric panniculitis is a rare inflammatory condition of mesenteric fat that can mimic malignancy on imaging, complicating clinical management. This study aimed to clarify the relationship between systemic melanoma therapies and MP incidence.

Data Highlights

Key Findings

• Among 490 melanoma patients, 384 received ICI and 106 received BRAFi/MEKi as first-line therapy.
• BRAFi/MEKi treatment was associated with a higher incidence of mesenteric panniculitis compared to ICI.
• MP was defined radiologically by characteristic mesenteric fat changes and confirmed by clinical and histopathological data when available.
• Patients in both groups had similar demographic and tumor stage distributions, minimizing confounding factors.
• MP can mimic malignancy on imaging, emphasizing the importance of accurate diagnosis to avoid misinterpretation.

Clinical Implications

Clinicians should be aware of the increased risk of mesenteric panniculitis in melanoma patients treated with BRAFi/MEKi. Recognizing MP’s imaging features is critical to differentiate it from metastatic disease and prevent unnecessary interventions. Monitoring for gastrointestinal symptoms and appropriate imaging follow-up is recommended during BRAFi/MEKi therapy.

Conclusion

BRAFi/MEKi therapy in advanced melanoma patients is linked to a higher risk of developing mesenteric panniculitis compared to ICI treatment. Awareness and accurate diagnosis of MP are essential to optimize patient management and avoid misdiagnosis.

References

1. Melanoma incidence and mortality statistics [1,2]
2. Advances in melanoma systemic therapies [3,4,5,6]
3. BRAFi/MEKi and ICI toxicity profiles [8,9,10]
4. Panniculitis associated with BRAFi/MEKi [11,12,13,14]
5. Mesenteric panniculitis imaging and clinical features [16,17,18,19,20]